Physicians see ‘new era for weight loss medications’ with the arrival of Novo, Lilly GLP-1 meds, survey says
Physicians are calling out two new obesity treatments — tirzepatide and semaglutide — as “paradigm shifting,” according to a new survey from InCrowd.
More than three-fourths of the endocrinologists and primary care physicians surveyed viewed tirzepatide first (77%) and semaglutide second (76%) as game-changers for the industry, with the next closest drug liraglutide at just 24%. InCrowd surveyed 100 doctors who had all treated at least 20 patients for weight loss in the past month. The survey also allowed for comments including one who said the treatments herald “a new era for weight loss medications.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
